Relmada Therapeutics, Inc. (RLMD) Dividend History

Company News

• Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

  Relmada Therapeutics announced positive Phase 2 data for its investigational drug NDV-01 in patients with high-grade non-muscle invasive bladder cancer. The data showed strong clinical activity and favorable tolerability, supporting further development of NDV-01.

  GlobeNewswire Inc.
• UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

  Relmada Therapeutics announced the presentation of an abstract at the American Urology Association (AUA2025) conference, highlighting the results of a prospective open-label study evaluating the safety and efficacy of their investigational drug NDV-01 for high-risk non-muscle invasive bladder cancer (HG-NMIBC).

  GlobeNewswire Inc.
• Comprehensive Market Analysis of Latest Published Different Types of Depression Reports | DelveInsight

  The depression treatment market is experiencing steady growth, driven by rising mental health awareness, increasing prevalence of depression, and advancements in novel therapies. The market is expanding with the introduction of innovative antidepressants, psychedelic-based treatments, and digital therapeutics.

  GlobeNewswire Inc.

  Featured Companies: ATAI AXSM GHRS JNJ LPCN SAGE
• Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017

  Relmada Therapeutics announced the discontinuation of its Reliance II and Relight Phase 3 studies for REL-1017 due to recent data monitoring committee evaluation. The company will continue to advance the Phase 1 study of REL-P11 and explore strategic alternatives to maximize shareholder value.

  Benzinga
• Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying

  The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Processa Pharmaceuticals The Trade: Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) CEO George Ng acquired a total of 10,000 shares an average price of $2.70. To acquire these shares, it cost around $27,000. The company’s Director Justin W Yorke also bought 8,000 shares of the company. What’s Happening: ...

  Benzinga

  Featured Companies: PAYS PCSA